ProCE Banner Activity

Phase II Trial: Nivolumab or Ipilimumab With or Without Azacitidine in Myelodysplastic Syndromes

Slideset Download
Conference Coverage
Immune checkpoint inhibitors ipilimumab and nivolumab were active in MDS, both individually in the setting of HMA failure and combined with 5-azacitidine in the frontline setting, producing promising survival and response outcomes with acceptable toxicity profiles.

Released: December 12, 2018

Expiration: December 11, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology